Clinical research applications of proteomics increasingly rely on MS-based approaches. Biomarker discovery, development, verification, validation, and quantification are all accessed using these approaches. Although different data collection modes exist for biomarker assessment, researchers are focusing on the emerging DIA mode in Combining Data-Independent Analysis (DIA) for Broad-Scale Phenotyping and Targeted Tandem Mass Spectrometry Quantification of Specific Biomarkers.
Rather than sampling a very well-defined set of peptides with tandem mass spectrometry, DIA sampling allows a broad acquisition of peptides that can be stored and queried at later time points. The ability to re-visit the DIA samples with new or emerging questions and mine that dataset using spectral library matching is the advantage of the DIA workflow over existing techniques (Sajic et al., 2015). Koomen discusses how he uses a database of all the mutant peptides that might be relevant to cancer and later come back and query the existing datasets to see if you’re able to observe those peptides.
For research use only. Not for use in diagnostic procedures.